Predicting cognitive decline in older people by structural and molecular imaging.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
19
7
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Availability of possible disease modifying treatments and the recognition of predementia stages of Alzheimer's disease (AD) have raised awareness for the prognostic and predictive role of biomarkers, particularly imaging markers. The positive predictive value of amyloid PET for the transition to prodromal AD or AD dementia in cognitively normal people is below 25%. Evidence for tau PET, FDG-PET and structural MRI is even more limited. In people with mild cognitive impairment (MCI), imaging markers yield positive predictive values above 60% with moderate advantages for amyloid PET over the other modalities and an added value for the combination of molecular with downstream neurodegeneration markers. In cognitively normal people, imaging is not recommended for individual prognosis due to lack of sufficient predictive accuracy. Such measures should be restricted to risk enrichment in clinical trials. In people with MCI, amyloid PET and, to a somewhat lesser extent, tau PET, FDG-PET, and MRI yield relevant predictive accuracy for clinical counseling as part of a comprehensive diagnostic program in tertiary care units. Future studies should focus on the systematic and patient-centered implementation of imaging markers in evidence-based care-pathways for people with prodromal AD.
Identifiants
pubmed: 37382114
doi: 10.1097/WCO.0000000000001172
pii: 00019052-990000000-00083
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Biomarkers
0
Amyloid beta-Peptides
0
tau Proteins
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253-263Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018; 14:535–562.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:270–279.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280–292.
Steinacker P, Huss A, Mayer B, et al. Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration 2017; 18:112–119.
Lin CH, Li CH, Yang KC, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 2019; 93:e1104–e1111.
Barro C, Healy BC, Liu Y, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2023; 10: [Epub ahead of print].
Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66:1469–1475.
Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69:181–192.
Rostamzadeh A, Bohr L, Wagner M, et al. Progression of subjective cognitive decline to MCI or dementia in relation to biomarkers for Alzheimer disease: a meta-analysis. Neurology 2022; 99:e1866–e1874.
Farrell ME, Papp KV, Buckley RF, et al. Association of emerging beta-amyloid and tau pathology with early cognitive changes in clinically normal older adults. Neurology 2022; 98:e1512–e1524.
Mayblyum DV, Becker JA, Jacobs HIL, et al. Comparing PET and MRI biomarkers predicting cognitive decline in preclinical Alzheimer disease. Neurology 2021; 96:e2933–e2943.
Pelkmans W, Legdeur N, Ten Kate M, et al. Amyloid-beta, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. Ann Clin Transl Neurol 2021; 8:348–358.
Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. Eur J Nuclear Med Mol Imaging 2022; 49:3508–3528.
Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015; 11:1–15.
Schaeverbeke JM, Gabel S, Meersmans K, et al. Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. Alzheimers Res Ther 2021; 13:75–91.
Farrell ME, Jiang S, Schultz AP, et al. Defining the lowest threshold for amyloid-pet to predict future cognitive decline and amyloid accumulation. Neurology 2021; 96:e619–e631.
Grothe MJ, Barthel H, Sepulcre J, et al. In vivo staging of regional amyloid deposition. Neurology 2017; 89:2031–2038.
Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006; 2006:re1.
Teipel SJ, Dyrba M, Chiesa PA, et al. In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. Neurobiol Aging 2020; 93:98–108.
de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98:10966–10971.
Drzezga A, Altomare D, Festari C, et al. Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. Eur J Nuclear Med Mol Imaging 2018; 45:1487–1496.
Kwan ATH, Arfaie S, Therriault J, et al. Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Commun 2023; 5:fcac325.
Chen X, Cassady KE, Adams JN, et al. Regional tau effects on prospective cognitive change in cognitively normal older adults. J Neurosci 2021; 41:366–375.
Chen SD, Lu JY, Li HQ, et al. Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Transl Psychiatry 2021; 11:483.
Karaman BK, Mormino EC, Sabuncu MR. Alzheimer's Disease Neuroimaging I. Machine learning based multimodal prediction of future decline toward Alzheimer's disease: an empirical study. PloS one 2022; 17:e0277322.
Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 2010; 40:135–145.
Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol 2021; 78:961–971.
Biel D, Brendel M, Rubinski A, et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther 2021; 13:137.
Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer's Disease’. The Ronald and Nancy Reagan Research Institute of the Alzheimer's association and the national institute on aging working group. Neurobiol Aging 1998; 19:109–116.
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321:1286–1294.
Teipel S, Spottke A, Boecker H, et al. Patient-related benefits of amyloid PET imaging in dementia: rationale and design of the German randomized coverage with evidence development study ENABLE. Alzheimer Dementia TRCI 2023; Still in press.
Schreiber S, Landau SM, Fero A, et al. Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes. JAMA Neurol 2015; 72:1183–1190.
Ruan D, Sun L. Amyloid-beta PET in Alzheimer's disease: a systematic review and Bayesian meta-analysis. Brain Behav 2023; 13:e2850.
Sorensen A, Blazhenets G, Schiller F, et al. Amyloid biomarkers as predictors of conversion from mild cognitive impairment to Alzheimer's dementia: a comparison of methods. Alzheimers Res Ther 2020; 12:155.
Smailagic N, Lafortune L, Kelly S, et al. 18F-FDG PET for prediction of conversion to Alzheimer's disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimers Dis 2018; 64:1175–1194.
Zhu L, Zhao W, Chen J, et al. Systematic review and meta-analysis of diagnostic test accuracy (DTA) studies: the role of cerebral perfusion imaging in prognosis evaluation of mild cognitive impairment. Ann Palliat Med 2022; 11:673–683.
Sorensen A, Blazhenets G, Rucker G, et al. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. Neuroimage Clin 2019; 21:101637.
Blazhenets G, Ma Y, Sorensen A, et al. Principal components analysis of brain metabolism predicts development of Alzheimer dementia. J Nucl Med 2019; 60:837–843.
Chandra A, Valkimadi PE, Pagano G, et al. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. Hum Brain Mapp 2019; 40:5424–5442.
Coomans EM, Verberk IMW, Ossenkoppele R, et al. A head-to-head comparison between plasma pTau181 and Tau PET along the Alzheimer's disease continuum. J Nucl Med 2023; 64:437–443.
Chen Y, Qian X, Zhang Y, et al. Prediction models for conversion from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis. Front Aging Neurosci 2022; 14:840386.
van Maurik IS, Vos SJ, Bos I, et al. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurol 2019; 18:1034–1044.
Lombardi G, Crescioli G, Cavedo E, et al. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. Cochrane Database Syst Rev 2020; 3:CD009628.
Seo EH, Park WY, Choo IH, Structural MRI. Amyloid PET imaging for prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment: a meta-analysis. Psychiatry Invest 2017; 14:205–215.
Shaffer JL, Petrella JR, Sheldon FC, et al. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology 2013; 266:583–591.
Liu X, Chen K, Wu T, et al. Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer's disease. Transl Res 2018; 194:56–67.
Ritter K, Schumacher J, Weygandt M, et al. Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers. Alzheimer's & Dement Diagn Assess Dis Monit 2015; 1:206–215.
Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015; 313:1939–1949.
Altomare D, Ferrari C, Caroli A, et al. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. J Neurol 2019; 266:2535–2545.
Schmand B, Eikelenboom P, van Gool WA. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 2012; 29:641–648.
Matsunari I, Samuraki M, Chen WP, et al. Comparison of 18F-FDG PET and optimized voxel-based morphometry for detection of Alzheimer's disease: aging effect on diagnostic performance. J Nucl Med 2007; 48:1961–1970.
Ferretti MT, Iulita MF, Cavedo E, et al. Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol 2018; 14:457–469.
Altomare D, Barkhof F, Caprioglio C, et al. clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: the AMYPAD-DPMS randomized clinical trial. JAMA Neurol 2023.
Chiotis K, Dodich A, Boccardi M, et al. Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nuclear Med Mol Imaging 2021; 48:2086–2096.
Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol 2017; 16:661–676.
Boccardi M, Dodich A, Albanese E, et al. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nuclear Med Mol Imaging 2021; 48:2070–2085.
Zhang S, Smailagic N, Hyde C, et al. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2014; 7:CD010386.
Martinez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11:CD012884.
Martinez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11:CD012216.
Martinez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 2017; 11:CD012883.
Gomez-Sancho M, Tohka J, Gomez-Verdejo V. Alzheimer's Disease Neuroimaging I. Comparison of feature representations in MRI-based MCI-to-AD conversion prediction. Magn Reson Imaging 2018; 50:84–95.
Farrar G, Molinuevo JL, Zanette M. Is there a difference in regional read [(18)F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment? European journal of nuclear medicine and molecular imaging 2019; 46:1299–1308.
Drzezga A. Diagnosis of Alzheimer's disease with [18F] PET in mild and asymptomatic stages. Behav Neurol 2009; 21:101–115.